TY - JOUR
T1 - Invasive Nocardia Infections across Distinct Geographic Regions, United States
AU - Gupta, Simran
AU - Grant, Leah M.
AU - Powers, Harry R.
AU - Kimes, Kathryn E.
AU - Hamdi, Ahmed
AU - Butterfield, Richard J.
AU - Gea-Banacloche, Juan
AU - Vijayvargiya, Prakhar
AU - Hata, D. Jane
AU - Meza Villegas, Diana M.
AU - Dumitrascu, Adrian C.
AU - Harris, Dana M.
AU - Chirila, Razvan M.
AU - Zhang, Nan
AU - Razonable, Raymund R.
AU - Kusne, Shimon
AU - Alvarez, Salvador
AU - Vikram, Holenarasipur (HR) R
N1 - Publisher Copyright:
© 2023 Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2023
Y1 - 2023
N2 - We reviewed invasive Nocardia infections in 3 noncontiguous geographic areas in the United States during 2011–2018. Among 268 patients with invasive nocardiosis, 48.2% were from Minnesota, 32.4% from Arizona, and 19.4% from Florida. Predominant species were N. nova complex in Minnesota (33.4%), N. cyriacigeorgica in Arizona (41.4%), and N. brasiliensis in Florida (17.3%). Transplant recipients accounted for 82/268 (30.6%) patients overall: 14 (10.9%) in Minnesota, 35 (40.2%) in Arizona, and 33 (63.5%) in Florida. Manifestations included isolated pulmonary nocardiosis among 73.2% of transplant and 84.4% of non–transplant patients and central nervous system involvement among 12.2% of transplant and 3.2% of non–transplant patients. N. farcinica (20.7%) and N. cyriacigeorgica (19.5%) were the most common isolates among transplant recipients and N. cyriacigeorgica (38.0%), N. nova complex (23.7%), and N. farcinica (16.1%) among non–transplant patients. Overall antimicrobial susceptibilities were similar across the 3 study sites.
AB - We reviewed invasive Nocardia infections in 3 noncontiguous geographic areas in the United States during 2011–2018. Among 268 patients with invasive nocardiosis, 48.2% were from Minnesota, 32.4% from Arizona, and 19.4% from Florida. Predominant species were N. nova complex in Minnesota (33.4%), N. cyriacigeorgica in Arizona (41.4%), and N. brasiliensis in Florida (17.3%). Transplant recipients accounted for 82/268 (30.6%) patients overall: 14 (10.9%) in Minnesota, 35 (40.2%) in Arizona, and 33 (63.5%) in Florida. Manifestations included isolated pulmonary nocardiosis among 73.2% of transplant and 84.4% of non–transplant patients and central nervous system involvement among 12.2% of transplant and 3.2% of non–transplant patients. N. farcinica (20.7%) and N. cyriacigeorgica (19.5%) were the most common isolates among transplant recipients and N. cyriacigeorgica (38.0%), N. nova complex (23.7%), and N. farcinica (16.1%) among non–transplant patients. Overall antimicrobial susceptibilities were similar across the 3 study sites.
UR - http://www.scopus.com/inward/record.url?scp=85178544179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85178544179&partnerID=8YFLogxK
U2 - 10.3201/eid2912.230673
DO - 10.3201/eid2912.230673
M3 - Article
C2 - 37987603
AN - SCOPUS:85178544179
SN - 1080-6040
VL - 29
SP - 2417
EP - 2425
JO - Emerging infectious diseases
JF - Emerging infectious diseases
IS - 12
ER -